Dedicated to Significant Progress

At Astellas, our commitment to R&D is based on the development of first-in-class and best-in-class products in our therapeutic areas of focus. In the U.S., Astellas has a robust pipeline of products in clinical development, which is supported through our:

  • Focus on research and development in key therapeutic areas, including cardiology, immunology, infectious disease, oncology and urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients and our partners.

  • Commitment to discovering and developing innovative therapies that address unmet medical needs in areas such as oncology. Agensys, Inc., a subsidiary of Astellas Pharma Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers. Agensys is furthering a pipeline of both naked and antibody-drug conjugated (ADC) therapeutic antibodies, directed at a variety of cancer indications, including those of the prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin.

  • Ability to maximize our broad research network to research and develop innovative drugs. At Astellas, we are committed to discovering novel biological targets and new chemical entities with unique mechanisms. We are able to pursue a wide range of leads for innovative drugs, including chemical compounds, natural substances, and proteins created by genomic technologies, through the full range of state-of-the-art technologies.

  • Dedication to growing our highly focused, efficient and scientifically meaningful development program. Clinical studies that benefit our global development program are conducted at our headquarters for the Americas located in Northbrook, Illinois. In 2008, Astellas relocated its Astellas Pharma Global Development headquarters from Japan to the United States.

For more information about our Clinical Study results, please visit our site: www.astellasclinicalstudyresults.com.

For more information about our global research and development capabilities, please visit the Astellas Pharma Inc., Web site.

Copyright © 2005 - 2009 Astellas Pharma US, Inc.